The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565. We have recently invited stakeholders to respond to a written consultation on the draft scope.
On receiving updated regulatory timing information from the company that is developing venetoclax with bortezomib and dexamethasone, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.